Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study

Area of Science:

• Hematology
• Oncology
• Cytogenetics

Background:

• The deletion of the long arm of chromosome 6 (del(6q)) is the most frequent cytogenetic abnormality observed in Waldenstrom's macroglobulinemia (WM).
• The prognostic value of this specific genetic alteration in WM remains uncertain.
• Understanding the clinical significance of del(6q) is crucial for patient management and treatment strategies.

Purpose of the Study:

• To investigate the prognostic significance of 6q deletions in Waldenstrom's macroglobulinemia.
• To correlate the presence of 6q deletions with clinical features and patient survival outcomes.
• To determine if del(6q) is a reliable indicator for predicting disease progression or treatment response in WM.

Main Methods:

• Seventy-seven patients diagnosed with Waldenstrom's macroglobulinemia were included in the study.
• Interphase cytoplasmic immunoglobulin M fluorescence in situ hybridization (cIgM-FISH) was employed to detect hemizygous 6q deletions.
• The status of 6q deletions was analyzed in conjunction with clinical data, laboratory features, and survival information.

Main Results:

• Hemizygous 6q deletions were identified in 41.6% (32 out of 77) of the WM patients.
• A statistically significant correlation was observed between 6q deletions and elevated C-reactive protein levels (P = .02) and CD23 expression (P = .03).
• No significant differences were found in the time to initial treatment or overall survival between patients with and without 6q deletions.

Conclusions:

• The study confirms that 6q deletion is a common cytogenetic finding in Waldenstrom's macroglobulinemia.
• Despite its frequency, the 6q deletion does not appear to influence key clinical outcomes such as time to treatment or overall survival.
• The prognostic impact of del(6q) in WM patients remains insignificant based on this investigation.